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Abstract 
PDRG1 is a small oncogenic protein of 133 residues. 
In normal human tissues, the p53 and DNA damage-
regulated gene 1 (PDRG1 ) gene exhibits maximal 
expression in the testis and minimal levels in the liver. 
Increased expression has been detected in several tumor 
cells and in response to genotoxic stress. High-throughput 
studies identified the PDRG1 protein in a variety of 
macromolecular complexes involved in processes that are 
altered in cancer cells. For example, this oncogene has 
been found as part of the RNA polymerase Ⅱ complex, 
the splicing machinery and nutrient sensing machinery, 
although its role in these complexes remains unclear. 
More recently, the PDRG1 protein was found as an 
interaction target for the catalytic subunits of methionine 
adenosyltransferases. These enzymes synthesize 
S-adenosylmethionine, the methyl donor for, among 
others, epigenetic methylations that occur on the DNA and 
histones. In fact, downregulation of S-adenosylmethionine 
synthesis is the first functional effect directly ascribed to 
PDRG1. The existence of global DNA hypomethylation, 
together with increased PDRG1 expression, in many tumor 
cells highlights the importance of this interaction as one 
of the putative underlying causes for cell transformation. 
Here, we will review the accumulated knowledge on 
this oncogene, emphasizing the numerous aspects that 
remain to be explored.
Key words: Epigenetic modifications; Glutathione; 
Methylation; Oncogenes; Intermediary metabolism; p53 
and DNA damage-regulated gene 1; Protein complexes; 
R2TP/prefoldin complex; S-adenosylmethionine synthesis; 
Redox stress
© The Author(s) 2017. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: PDRG1 is an understudied protein of the 
R2TP/prefoldin-like complex that has been found as 
part of different multiprotein complexes. Increased 
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PDRG1 expression levels have been associated with 
several types of tumors that concomitantly show global 
DNA hypomethylation. More recently, this protein has 
been uncovered as an interaction target for methionine 
adenosyltransferase catalytic subunits MATα1 and 
MATα2. Through this interaction, PDRG1 downregulates 
nuclear S-adenosylmethionine synthesis, hence impacting 
epigenetic methylations.
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INTRODUCTION
Late in the 20th century, global DNA hypomethylation 
was described as a main characteristic of cancer cells 
and as the underlying cause of their altered expression 
pattern[1,2]. Moreover, tumor cell growth was found to 
be totally dependent on glutamine and methionine, 
and the latter amino acid could not be replaced by 
homocysteine[3]. Methionine is one of the substrates 
required for the synthesis of the main cellular methyl 
donor, S-adenosylmethionine (AdoMet), which is used 
for epigenetic methylations occurring at both the 
DNA and its associated proteins for the regulation of 
gene expression. These modifications are among the 
dozens of methylation reactions that occur in a cell 
using S-adenosylmethionine (AdoMet) as a methyl 
donor[4,5]. However, the methyltransferases catalyzing 
these modifications are not the main consumers of 
AdoMet, despite their importance in regulating cell 
function. This fact is especially clear in the liver, where 
three methyltransferases involved in the synthesis of 
small compounds use the majority of the methyl donor 
synthesized[6,7]. Those are glycine N-methyltransferase 
(GNMT), guanidinoacetate N-methyltransferase (GAMT) 
and phosphatidylethanolamine N-methyltransferase 
(PEMT), which produce sarcosine, creatine and phosp-
hatidylcholine, respectively[8-11]. Nevertheless, these 
estimations were made on the basis that AdoMet 
synthesis occurs exclusively in the cytoplasm and 
that the methyl donor would be transported to other 
subcellular localizations as required. This assumption has 
been challenged lately by reports describing the existence 
of nuclear pools of several enzymes of the methionine 
cycle, the pathway where AdoMet is produced, in 
turn suggesting the existence of two independent 
AdoMet stocks in the cytoplasm and the nucleus[12-16]. 
The existence of a nuclear branch of this pathway is 
supported by the importance of epigenetic methylations 
and the need to guarantee their AdoMet supply.
To date, information regarding the cytoplasmic and 
nuclear branches of the methionine cycle has been 
mainly obtained in liver, and the accumulated knowledge 
can be summarized as follows. The cytoplasmic 
methionine cycle involves the following (Figure 1): (1) 
methionine adenosyltransferases (MATs) that synthesize 
AdoMet; (2) a large number of methyltransferases, which 
methylate many types of substrates, also rendering 
S-adenosylhomocysteine (AdoHcy); (3) AdoHcy 
hydrolase (AHCY), which eliminates AdoHcy leading to 
adenosine and homocysteine (Hcy); and (4) betaine 
homocysteine S-methyltransferases (BHMT and BHMT2) 
and methionine synthase (MTR), which methylate Hcy to 
obtain methionine using betaine or S-methylmethionine 
and 5-methyltetrahydrofolate, respectively[17,18]. In 
contrast, the nuclear branch of the pathway involves a 
more reduced set of enzymes as follows (Figure 1): (1) 
MATs; (2) methyltransferases such as those involved 
in DNA and histone methylations, GNMT and GAMT; 
(3) AHCY[12,13,15,16]; and (4) BHMT[19]. Of note, levels 
of MATs, GNMT and AHCY are markedly higher in the 
cytoplasm than in the nucleus, but increases in the 
latter compartment can be observed as a consequence 
of pathological changes in glutathione concentrations 
and, precisely, decreases in the GSH/GSSG ratio[14]. 
More recently, PDRG1 [Consensus nomenclature for 
the human (PDRG1) and mouse genes (Pdrg1) is used 
throughout the text. The protein is in all the cases 
referred to as PDRG1] was added to this nuclear branch 
of the cycle as an interaction target and regulator of 
MATs, and hence, of AdoMet synthesis[20,21]. 
PDRG1 stands for p53 and DNA damage-regulated 
gene 1 as it was discovered during studies devoted to the 
identification of components of the cellular response to 
DNA damage, or genotoxic stress, and it is regulated by 
p53[22]. However, what do we really know about PDRG1? 
This is the question that will be addressed in the next 
sections of the present mini-review.
PDRG1 GENE STRUCTURE AND 
REGULATION
Studies devoted to the identification of components of 
the cellular response to DNA damage have been carried 
out for a number of years, and many of them used UV-
irradiation as a stressor. Some of these investigations 
identified several novel UV-induced genes using a UV-
treated low-ratio hybridization subtraction-enriched cDNA 
hamster library, and they were followed by screenings 
of partial-length expressed sequence tag (EST) clones 
regulated by this type of stress[22-24]. This latter procedure 
rendered a UV-induced EST clone that hybridized 
with a 1.4 kb transcript, which was named PDRG1[22]. 
Sequencing of the corresponding human and mouse 
EST clones from different tissues showed a single open 
reading frame coding for a protein of 133 amino acids.
The PDRG1 gene is organized among five exons 
and four introns in both humans and mice (Figure 2)[22]. 
The start codon is located at position 120 in exon 1 of 
the human gene, whereas the stop codon occurs at 
position 85 on exon 5. The mouse gene is located on 
chromosome 2, whereas the human gene appears on the 
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long arm of chromosome 20 at the 20q11.2 region[22]. 
Interestingly, the human gene localization coincides 
with a position in which gains of DNA are detected in 
hepatocellular carcinoma (HCC) and dysplastic nodules, 
and where alterations in cirrhotic processes are also 
found[25]. Moreover, these are pathologies in which 
impairment of the methionine cycle, especially of AdoMet 
production, have been described[17].
Analysis of the human PDRG1 promoter was initially 
carried out using a 1.7 kb fragment that included the 
5’-UTR and part of the non-coding region of exon 1, 
and it showed high levels of promoter activity in breast 
cancer MCF-7 cells when fused to the luciferase gene[22]. 
The gene contains a TATA-like element (TAATAA) 
localized at -268 from the start codon, but no canonical 
TATA box was identified[22]. Promoter activity was 
eliminated by deletion of the -138/+1 region, in turn 
suggesting the presence of key regulatory elements in 
this segment[22]. These same authors also detected two 
putative downregulatory elements in the promoter. The 
first, a p53 binding element, was identified at position 
-240/-214 and includes two RRRCWWGYYY (R = purine, 
Y = pyrimidine, W = A or T, S = G or C, D = A, G or T) 
repeats arranged head to tail and separated by a 6 bp 
sequence[26-28]. The second corresponds to a putative 
p53 transcriptional repressor element (TRE) located at 
-854/-834[29]. Regulation of the PDRG1 promoter by 
p53 was further proven when luciferase activity was 
abolished in the presence of this tumor suppressor[22]. 
Basal PDRG1 expression in p53 null HCT116 colon 
cancer cells was in fact higher than that in their wild-
type counterparts, results that further supported 
repression of PDRG1 by p53.
Additionally, the PDRG1 promoter includes a canonical 
Oct-1 binding element located at -689/-683[22,30]; this 
factor is known to upregulate expression of a number of 
genes when activated by UV irradiation[31,32]. Cotransfection 
of a PDRG1 promoter-luciferase construct and Oct-1 into 
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Figure 1  The cytoplasmic and nuclear branches of the hepatic methionine cycle and transsulfuration. Essential components (metabolites and enzymes) 
of the pathways are shown in the figure. Cytoplasmic enzymes appear in aquamarine boxes, their nuclear equivalents are shown in green boxes, and protein 
interaction targets are depicted in orange. Only key methyltranferases (MTs) mentioned in the text are illustrated in both subcellular compartments. The 
nucleocytoplasmic transport of metabolites (blue arrows) and enzymes (maroon arrows) is shown, whereas protein interactions are indicated by violet arrows. 
AdoHcy: S-adenosylhomocysteine; AdoMet: S-adenosylmethionine; AHCY: S-adenosylhomocysteine hydrolase; BHMT: Betaine homocysteine S-methyltransferase; 
CBS: Cystathionine b-synthase; DNMT: DNA methyltransferase; GAMT: Guanidinoacetate N-methyltransferase; GNMT: Glycine N-methyltransferase; HMT: Histone 
methyltransferase; MATs: Methionine adenosyltransferases; MTR: Methionine synthase; NPC: Nuclear pore complex; PDRG1: p53 and DNA damage-regulated gene 1; 
PEMT: Phosphatidylethanolamine N-methyltransferase; X-CH3: Methylated acceptors (metabolites, proteins, DNA, etc).
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MCF-7 cells rendered approximately 8-fold induction of 
the luciferase activity, thus demonstrating the functionality 
of this Oct-1 binding element[22]. This increased promoter 
activity was far greater than that caused exclusively by UV 
irradiation, a fact that Luo et al[22] ascribed putatively to 
p53 activation in these cells.
More recently, the presence of complementary 
sequences for miR-214 (position 842-850) and miR-519d 
(position 1076-1082) in the 3’-UTR of the PDRG1 mRNA 
was reported[33,34]. Overexpression of miR-214, a miRNA 
with dual functionality as tumor suppressor or oncogene, 
in bladder cancer cell lines reduced PDRG1 expression 
and protein levels[33]. Similarly, overexpression of miR-
519d leads to decreased PDRG1 mRNA and protein levels 
in two nasopharyngeal carcinoma cell lines, which in 
turn correlates with a higher radiation-induced mortality 
(Figure 3)[34].
Regarding the PDRG1 expression profile, this aspect 
was initially studied using commercial human poly(A)+ 
Northern blots, where a 1.4 kb transcript was identified 
in brain, heart, liver, lung, spleen, stomach, testis and 
skeletal muscle[22]. More recently, real-time RTqPCR of 
rat tissues also demonstrated wide expression of Pdrg1, 
further including the cerebellum, intestine, pancreas, 
kidney and cava vein[20]. In human tissues the highest 
levels were found in testis, whereas in the rat similar 
expression levels were detected in brain, cerebellum 
and testis. Nevertheless, both species showed very low 
PDRG1 expression in the liver[20,22]. 
PDRG1 PROTEIN
Mammalian PDRG1 proteins share a high level of 
conservation, and most of them are over 90% identical 
(Figure 4). The sequences usually comprise 133 residues 
(15.5 kDa for the human protein), although larger proteins 
have been predicted in several marine mammals. In 
those cases, PDRG1 presents with N-terminal extensions 
of variable length. The protein’s isoelectric point is 5.81, 
and several post-translational modifications have been 
predicted and identified in high-throughput studies. 
Among them, phosphorylations at human serine residues 
p53TRE
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1               2                3                4                     5
TGA
p53
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1 ATG
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1                         133
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Figure 2  Regulatory elements on the human PDRG1 gene and mRNA and structural features of the protein. From top to bottom, the figure shows first a 
scheme of the human PDRG1 gene, indicating the regulatory elements on the promoter identified to date as follows: p53 and p53TRE elements (red), an Oct-1 
binding element (green) and the TATA-box-like element (crimson). Exons appear as blue boxes. Second, a schematic representation of the mRNA is depicted, 
including the ORF (blue box) and the miRNA binding sites identified at the 3’-UTR (aquamarine boxes). Third, a scheme of the PDRG1 protein is shown where the 
sequence encoding the prefoldin-like domain is indicated as a crimson box. Finally, a cartoon of the modeled prefoldin-like domain of rat PDRG1 is included with the 
N-terminal K27 (red) and the C-terminal Q106 (magenta) depicted as sticks.
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3, 52, 54 and mouse serine 120 and ubiquitinations 
on human lysine residues 27, 108 and 125 have been 
postulated or found[35-41]. Initial studies suggested 
association of the protein into homo-oligomers, a fact that 
was later confirmed by detection of HA-PDRG1 hexamers 
in embryonic kidney HEK293T cells using analytical gel 
Oleuropein
HIF1α
Oleuropein
HRE         HRE              ORF HRE         HRE             ORF
HIF1α
miR-519d miR-519d
ORF                 miR ORF                 miR
PDRG1 PDRG1
UV UV
Mortality Survival
Figure 3  Regulation of cell survival. A schematic representation of the effects on cell survival exerted by PDRG1 regulation through miR-519d expression is shown. 
Binding sites for HIF1a (HRE) in the promoter of the miR-519d gene (black box) and for this miRNA on the PDRG1 mRNA (white box) are indicated. Agents used for 
induction or blockade of UV-irradiation effects are indicated on the top.
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Figure 4  Alignment of mammalian PDRG1 proteins. The figure shows the BLASTP alignment of thirteen representative mammalian PDRG1 sequences using 
that of Rattus norvegicus as a reference. Most of the data correspond to predicted sequences (*). Conservative changes are highlighted in green, non-conservative 
substitutions appear in red, and N-terminal extensions are indicated in yellow. The C-terminal helix-turn-helix motif and the prefoldin-like domain are indicated in blue 
and crimson boxes, respectively.
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filtration chromatography[20-22].
Motif searches identified a helix-turn-helix (LNQDEL 
KALKVILKG) at the C-terminal end of the human and 
mouse protein sequences[22]. These motifs are normally 
involved in interactions with either the DNA or other 
proteins. Moreover, human and mouse PDRG1 are 
characterized by the presence of a b-prefoldin-like domain 
that is also recognized by the Protein Homology/analogY 
Recognition Engine (PHYRE) in the rat counterpart. 
PHYRE2 identified prefoldin as the closest homologue 
to rat PDRG1 during the preparation of a structural 
model. This model included residues K27-Q106 (Figure 
2), thus excluding approximately 25 residues from 
each protein end. Elimination of the C-terminal end has 
divergent effects on the interaction of PDRG1 with MAT 
catalytic subunits MATα1 and MATα2[20,21]. Additionally, 
motif searches carried out with the rat PDRG1 sequence 
predicted nucleocytoplasmic localization (PSORT Ⅱ) and 
a nuclear export signal (NES) involving serine 93; the 
NetNES score increases between residues E89-L95. 
Subcellular localization was initially examined by 
fluorescence microscopy using PDRG1-GFP and GFP-
PDRG1 tagged forms in fixed NIH 3T3 fibroblasts and 
HCT116 colon cancer cells. In both cases, cytoplasmic 
aggregates of the protein were described, whereas no 
localization within subcellular compartments such as the 
mitochondria, endoplasmic reticulum and nucleus was 
observed using specific dyes for these organelles[22]. 
Moreover, these authors indicated that this distribution 
was not affected by UV irradiation, and hence, a putative 
PDRG1-DNA interaction was excluded. In contrast, 
PDRG1 was found in the nuclear fractions used to isolate 
protein complexes from LNCaP prostate cancer cells, 
hence suggesting that the protein may be distributed 
between subcellular compartments[42]. This aspect was 
reexamined using confocal microscopy and several 
cell lines in which HA-PDRG1 or PDRG1-EGFP was 
overexpressed. The results of direct fluorescence and 
immunofluorescence experiments demonstrated that, 
in fact, PDRG1 is a nucleocytoplasmic protein in ovary 
(CHO), kidney (COS-7), neuroblastoma (N2a) and 
hepatoma (H35) cell lines[20,21]. Moreover, quantification 
of the fluorescence signals indicated a stronger protein 
level in the nuclear compartment, where PDRG1 also 
colocalized with nuclear speckles containing SC-35.
PROTEIN-PROTEIN INTERACTIONS 
INVOLVING PDRG1
Lately, several high-throughput studies have been 
carried out with the goal of identifying components of 
several large protein complexes (Figure 5). For this 
purpose, the following two main techniques were used: 
(1) affinity purification of subunits including single (AP) 
or tandem tags (TAP) followed by mass spectrometry 
(MS); and (2) yeast two-hybrid (YTH). During some of 
these studies PDRG1 was identified either as a subunit or 
interaction target of several complexes, and interestingly, 
methylation plays a direct or indirect role in many of 
the processes involving these multimers (e.g., nutrient 
signaling and mRNA capping). 
PDRG1 is indirectly linked to the RNA polymerase Ⅱ  
machinery
MS, together with a computer method to minimize 
the contribution of false positives, was used to identify 
the interaction network of human RNA polymerase Ⅱ 
RNA polymerase II
Chromatin remodeling
Apoptosis
Spliceosome
MethylationsR2TP/prefoldin complex
RUVL2XAB1
FLJ21909
RPB5
hSpagh
Art27
URI MATs
PDCD7
PDRG1
Figure 5  Schematic representation of the main PDRG1 interaction targets. The figure highlights the main targets of interaction with PDRG1 identified using 
either affinity purification/mass spectrometry or yeast two-hybrid screening. The proteins involved are shown in blue boxes within circles, according to the function or 
multiprotein complex in which they are involved. PDRG1 appears at the intersection of these circles.
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using tagged subunits that allowed TAP purification 
from kidney HEK293 cells[43]. Some key proteins were 
selected for additional TAP-MS experiments, and among 
them are XAB1, which appears placed at the interface 
with members of chaperone complexes (C19orf2/URI, 
PFDN6, PFDN2 and UXT), and the AAA+ chaperone-
like ATPases RUVBL1/TIP49a and RUVBL2/TIP49b. 
These experiments showed TAP-XAB1 copurification 
with FLJ21909 and subsequent TAP-FLJ21909 copu-
rification with PDRG1[43]. Moreover, this same work 
also demonstrated copurification of PDRG1 with TAP-
RUVBL2, C1orf82/RPAP2 and FLJ21908/RPAP3, although 
no further validation of the interactions using additional 
techniques was carried out[43]. 
Additional studies to analyze the cytoplasmic assembly 
of RNA polymerase Ⅱ were later performed by Boulon et 
al[44]. These MS-proteomics studies showed association of 
unassembled RPB1, the largest subunit of this transcription 
machinery, with the R2TP/prefoldin-like complex[44]. 
Moreover, in this same study the interactions of a central 
component of the R2TP/prefoldin-like complex, hSpagh 
that binds HSP90 as a cofactor, were further explored. 
Independent interactions of hSpagh with RPB1 and RPB5 
subcomplexes were then identified, which also involved 
other members of the R2TP/prefoldin-like complex, such 
as PDRG1. However, YTH only confirmed the implication of 
PDRG1 in the interaction with RBP5, although this binding 
seemed indirect through its association with hSpagh[44]. 
PDRG1 may have a role in chromatin remodeling, 
splicing and apoptosis
AP-MS data also suggested that PDRG1 might be 
linked to the SWR-C and INO80 chromatin remodeling 
complexes. Such a relationship could be established by 
the identification of its interaction targets, RUVBL1 and 
RUVBL2, in both complexes in experiments carried out 
in nuclear fractions of human cells[45,46]. Additionally, YTH 
screens identified PDRG1 interacting with programmed 
cell death 7 (PDCD7), Cip1 zinc interacting finger 
(CIZ1) and microtubule-associated protein 1S (MAP1S) 
in human testis, although immunoprecipitation only 
confirmed the PDRG1-PDCD7 interaction[47]. These 
results linked PDRG1 with the modulation of apoptosis 
and the U12-type spliceosome, a process and a complex 
that involve PDCD7[48]. 
PDRG1 is a member of the URI/prefoldin complex 
involved in nutrient signaling
PDRG1 was identified, together with HKE2, BC014022, 
POL3A, FLJ21908 and FLJ20643, as a new member 
of the URI/prefoldin complex with abundance similar 
to that exhibited by the consensus subunits known at 
that time[49]. URI stands for unconventional prefoldin 
RPB5 interactor, also known as RMP, and some of the 
interaction studies described in this section showed 
this interaction. Additional data from this AP-MS study 
identified PDRG1 interacting with TIP49a/b in HEK293/
FRT and HeLa cells, as well as bound to BC014022, 
DPCD, FLJ20643, NUFIP, RPB5MP and UXT1[49]. 
Reciprocal studies using FLAG-tagged PDRG1 identified 
interactors with moderate (POL3A, PPP1CA, PPP1CC, 
PFDN2, HKE2, RPB5, PPP1CB, NPM1, UXT1, H2BS, 
H2BR, RPB5MP, FLJ21908, BC014022, H2AZ, NOP5/
NOP58, FLJ20643) or low probability scores (TUB6, 
HSP70/1, HSP70/1B, BAF53, TIP49a, TIP49b)[49]. 
However, none of these PDRG1 interactions were 
confirmed by immunoprecipitation. More recently, 
MS analysis of immunoprecipitates from nuclear fra-
ctions of LNCaP prostate cells stably transfected with 
FLAG-URI also showed the presence of PDRG1 in the 
R2TP/prefoldin-like complex, and the interaction was 
confirmed by detection of URI and PDRG1 in anti-
Art27 immunoprecipitates[42]. Both studies considered 
the PDRG1-URI interaction abundant, according to the 
number of peptides retrieved[42,49].
PDRG1 overexpression did not modify URI or Art27 
levels, whereas overexpression of URI upregulates 
PDRG1 protein levels, an effect that was ascribed to 
protein stabilization[42]. The PDRG1-URI interaction 
seems to involve the hook-shaped b-strands of the 
URI N-terminal prefoldin-like domain, through which 
interaction with Art27 is also established. In fact, these 
authors suggested that all prefoldin-like proteins of the 
R2TP/prefoldin-like complex (URI, Art27, PDRG1, PFD2, 
PFD6) use the hook to interact with each other[42].
AP-MS experiments carried out in HeLa cells identified 
URI, TIP49/RUVL, RMP and RPB5 in association with 
STAP-1, and hence potentially linking PDRG1 with signal 
transduction and the TOR complex[50]. These interactions 
were further confirmed by immunoprecipitation, where 
anti-URI binds RPB5 and STAP-1 and anti-TIP48 rendered 
TIP49, URI, STAP1 and SKP2. Similarly, PDRG1 could be 
indirectly implicated in the roles of URI as a transcriptional 
repressor and as a regulator of apoptosis that involve 
interactions with the RPB5/POLR2E subunit of the three 
RNA polymerases and PPIγ[51,52]. In the latter case, 
phosphorylation of mitochondrial URI by S6K1 allows 
dissociation of the complex. Moreover, the URI complex 
is targeted by nutrient signaling and, in turn, participates 
in the control of gene expression downstream of the TOR 
kinase, a process that is regulated by methylation of the 
protein phosphatase PP2A[53]. 
PDRG1 controls production of S-adenosylmethionine
In yeast, URI deletion alters expression of genes involved 
mainly in amino acid metabolism, although none of the 
key genes in the methionine cycle seems affected[50]. 
On the other hand, YTH screening of a rat liver library 
identified PDRG1 interacting with MATα1, a result that 
was further confirmed by immunoprecipitation and pull-
down[20]. These results linked PDRG1 with methionine 
metabolism and AdoMet-dependent methylations[20], 
which are altered in tumor cells. 
MATα1 is the catalytic subunit of homotetrameric 
MAT Ⅰ and homodimeric MAT Ⅲ, the isoenzymes 
synthesizing AdoMet in normal liver, and accumulates 
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in the cell nucleus in liver disease and extrahepatic 
cells[12,14]. Despite the nucleocytoplasmic localization of 
both MATα1 and PDRG1, their interaction was restricted 
to the nuclear compartment, where large association 
states (approximately 360 kDa) could be detected[20,21]. 
Taking into account the size of each protein and their 
individual oligomeric states, this means binding of two 
PDRG1 hexamers per nuclear MAT Ⅰ homotetramer. 
Moreover, pull-down assays also showed the ability of 
PDRG1 to interact with the MATα2 catalytic subunit of 
heterotrimeric MAT Ⅱ, the main isoenzyme found in 
extrahepatic tissues, fetal liver and hepatic diseases[20,21]. 
This fact could be expected from the high percentage 
of identity (84%) between the MATα1 and MATα2 
subunits[54]. Additionally, the PDRG1-MATα2 interaction 
interface seems to overlap with the binding site for 
the regulatory MATb subunit that is displaced from the 
oligomer upon PDRG1 attachment[20]. Further insights 
into the putative areas of interaction were obtained 
through the use of truncated PDRG1 forms. These 
protein variants were designed according to information 
obtained from the available structural model and lack 
the N-terminus, the C-terminus or both protein ends[20]. 
Analysis of their interaction with MATα1 and MATα2 
indicated a role for the C-terminal end of PDRG1 in the 
interaction, an area that is not involved in the interaction 
with other members of the R2TP/prefoldin-like complex, 
which seem to use the hook for this purpose[42]. 
Tissue Pdrg1 expression mimics the expression profile 
of Mat2a (the MATα2 gene), while following the opposite 
pattern from that exhibited by Mat1a (the MATα1 
gene)[20]. This fact coincides with the preferential nuclear 
localization of MATα1 in those cell types/tissues where 
Mat1a expression is low, thus increasing the probability of 
interaction with PDRG1 in those settings. This interaction 
impairs AdoMet production by approximately 50%, as 
demonstrated in vitro using purified MATα1 or MATα2 
homo-oligomers or MAT Ⅱ hetero-oligomers and PDRG1. 
Similarly, decreased global DNA methylation levels were 
detected in cultured cells upon overexpression of PDRG1 
or coexpression of PDRG1 and MATα1[20,21]. Altogether, 
these results provide the first evidence for PDRG1 
function as a modulator of methyl donor production. 
ROLE OF PDRG1 IN DISEASE
To date, there is no disease directly linked to alterations 
in PDRG1, although the OMIM 610789 code has been 
associated with this gene. In fact, the NCBI database 
already includes descriptions of more than 700 SNPs 
in this gene, including point mutations in the ORF, 
frameshifts and early stop codons (Table 1). However, 
the impact of these alterations remains to be studied.
PDRG1 and cancer
The chromosomal location of PDRG1 coincides with 
a region with high frequency of sequence gains in 
several types of human cancers, including breast, 
liver, lung, colon and rectum tumors[25,55-59]. Moreover, 
p53 is downregulated in several human cancers, and 
hence, its regulation of the PDRG1 gene is expected 
to be impaired. The same is true for miR-214, which 
is also downregulated in cervical, breast, HCC and 
bladder tumors[33,60-62]. Using commercial cancer 
profiling arrays, 60%-85% upregulation of PDRG1 was 
detected in a variety of tumor types with impaired p53 
expression, confirming this hypothesis[47]. This same 
study also showed that the percentage of patients with 
increased PDRG1 levels was dependent on the type 
of tumor analyzed. In bladder cancer, miR-214 levels 
were associated with the tumor stage and recurrence, 
whereas an inverse correlation with PDRG1 expression 
was detected[33]. Moreover, this tumor suppressor role 
was found to be exerted through miR-214 binding to 
the 3’-UTR of the PDRG1 mRNA, in turn leading to a 
reduction in its levels.
Correlation of elevated PDRG1 and GLUT1 expression 
with poor pathological response has been reported 
in residual rectal cancer cells after pre-operative 
chemotherapy[63]. However, PDRG1 expression levels 
were not associated with the overall survival of the 
patients despite its proposed roles in DNA damage 
regulation and tumor growth. Furthermore, a role for 
PDRG1 in cancer can also be inferred from the reports 
linking its interaction target URI to the development 
of ovarian cancer and HCC[64,65]. In this same line, the 
reduced miR-214 levels found in breast cancer cells lead 
to the accumulation of the enhancer of Zeste homologue 
2 (EZH2) methyltransferase. EZH2 is a component 
of the polycomb repressive complex 2 (PRC2) and 
catalyzes the inclusion of the repressive epigenetic 
mark H3K27me3[61]. Levels of this repression mark 
are enhanced in HCC[66], where nuclear accumulation 
of MATα1 is induced, putatively favoring its interaction 
with PDRG1. This apparent contradictory effect could 
be explained by the high affinity of EZH2 for AdoMet, 
which putatively makes this particular methyltransferase 
insensitive to the decreased methyl donor concentrations 
resulting from the nuclear MATα1/PDRG1 interaction.
The upregulated expression of PDRG1 correlates 
with enhanced PDRG1 protein levels, for example in 
colon cancer samples (mainly in epithelial cells) and 
in some lung cancer cell lines (A549 and H446)[47,67]. 
Tumor cell lines have been used for stable or transient 
overexpression and downregulation of PDRG1 to study 
effects on proliferation, apoptosis or the response to 
UV irradiation. PDRG1 overexpression in A549 and 
H446 lung cancer cells enhanced proliferation, whereas 
no morphological changes in NIH 3T3 fibroblasts, 
HCT116 colon cancer or H35 hepatoma cells were 
observed[20,22,67]. Regarding apoptosis, no signs of this 
process were detected in NIH 3T3 or HCT116 cells 
after overexpression[22]. In contrast, downregulation 
of PDRG1 in T24 and 5637 bladder cancer cell lines by 
overexpression of miR-214 led to decreased proliferation, 
enhanced apoptosis and reduced invasiveness[33]. PDRG1 
knockdown in RKO colon and A549 and H446 lung 
cancer cells also caused reduction in cell growth[47,67]. 
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However, stable silencing in H35 hepatoma cells did not 
induce significant changes in growth of any of the clones 
analyzed or in their morphology[20]. This downregulation 
was never above 70%, suggesting that further sup-
pression of Pdrg1 expression in hepatoma cells could be 
lethal. Additionally, the differences observed may arise 
not only from the downregulation extent achieved in each 
tumor cell but also from the diverse procedures used for 
silencing and the distinct basal levels in the corresponding 
normal cells. Altogether, these results suggest a putative 
role for PDRG1 in apoptosis and proliferation, which might 
be exerted through its interaction with different targets. 
Among those identified to date, PDCD7 contributes to 
the modulation of apoptosis, MAP1S participates in cell 
cycle progression through its interaction with RASSF1A, 
and CIZ interacts with p21 for their shuttling from the 
nucleus to the cytoplasm.
Focusing our attention on stably silenced H35 
hepatoma cells, the maximum downregulation achieved 
is still well above the levels detected in normal liver[20,21]. 
Nevertheless, important changes in the expression 
profile were found using microarrays, these alterations 
affecting a large variety of pathways[20,21]. A total of 114 
genes consistently changed their pattern in different 
clones, of which only 80% could be ascribed to GO 
pathways. Among upregulated genes, Lpin1 was 
found. This is an essential gene in fat metabolism that 
is regulated by p53 and induced by DNA damage and 
glucose deprivation[68]. Lpin1 codes for a bifunctional 
protein that catalyzes diacylglycerol synthesis and acts 
as a transcriptional coactivator in hepatocytes to regulate 
fatty acid oxidation[68]. In contrast, expression of neither 
the Tp53 nor the Mat genes were significantly altered in 
the silenced cells, but many of the routes affected are 
implicated in pathological processes in which the pattern 
of Mat gene expression is modified[20,21]. 
As mentioned in the initial sections of this mini-
review, PDRG1 was identified when the effects of UV 
irradiation were analyzed. Therefore, it was not surprising 
that stable HCT116 clones overexpressing HA-PDRG1 
displayed increased sensitivity to UV irradiation or that 
this agent upregulated PDRG1 in several human cell lines, 
including some lacking p53 or carrying mutant forms 
of this protein[22]. In fact, higher PDRG1 mRNA levels 
were detected after irradiation upon TP53 repression by 
doxycycline in Tet-inducible DLD1 colon cancer cells as 
well as in TP53-/- cells. These data suggested an inverse 
correlation of PDRG1 and TP53 expression but also 
with that of Cip1 (the p21 gene, also named CDKN1), 
in turn indicating involvement of a p53-independent 
mechanism[22]. Additional studies carried out by Jiang et 
al[47] demonstrated that only agents inducing genotoxic 
stress (adriamycin, etoposide, camptothecin and UV) 
upregulated PDRG1 expression. 
The link between PDRG1 and radioresistance was 
further supported when an inverse correlation between 
PDRG1 and ATM levels was detected in lung cancer 
cells after irradiation[67]. In fact, PDRG1-silenced cells 
exhibited high ATM levels together with increased p53 
phosphorylation on serine 15, and tumors generated 
in nude mice using these silenced clones were more 
susceptible to irradiation[67]. Oleuropein treatment of 
nasopharyngeal cancer cell lines reduced PDRG1 and 
HIF1α expression and protein levels, while inducing 
miR-519d levels[34]. Further examination of the effects 
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Table 1  SNPs for the human PDRG1 gene listed in the NCBI 
database leading to mutated protein forms
SNP code1 Base change Mutated residue Type of mutation
rs777897331 1A>C M1L Missense
rs748585638 19G>A E7K Missense
rs867545839 23G>T R8L Missense
rs779425406 29T>C L10P Missense
rs755286962 32G>A R11Q Missense
rs150958567 34T>C Y12H Missense
rs142496377 35A>G Y12C Missense
rs375829085 46G>A V16M Missense
rs760411451 59C>T A20V Missense
rs763777690 57_68delCGCCG-
AGGAGGT
A20_V23del Indel
rs765247648 67G>T V23L Missense
rs759432900 83G>A R28Q Missense
rs772260316 91G>A V31M Missense
rs139473332 92T>C V31A Missense
rs147359616 110G>T R37M Missense
rs201481003 113A>C N38T Missense
rs749744129 119A>C N40T Missense
rs142890852 121C>G, 121C>T R41G, R41stop Missense, stop 
gained
rs539323269 122G>A R41Q Missense
rs746198655 134G>A R45K Missense
rs370045763 155G>C S52T Missense
rs758120112 157C>G L53V Missense
rs748723095 175G>T V59F Missense
rs775880591 184G>A G62R Missense
rs200644098 188A>G N63S Missense
rs767238840 190A>G M64V Missense
rs764202244 208C>T H70Y Missense
rs777531663 210_211insAA P71Nfs Frameshift 
rs566583428 211C>T P71S Missense
rs768828941 223_224ins2 E75Vfs Frameshift
rs750997250 251_252delTG L84Rfs Frameshift 
rs745401995 264A>G I88M Missense
rs780722451 265G>C E89Q Missense
rs201754951 274C>T R92W Missense
rs186921219 275G>A R92Q Missense
rs140650422 295G>A V99I Missense
rs200378363 299A>T N100I Missense
rs565384763 301C>T R101C Missense
rs779220725 302G>A R101H Missense
rs753937019 317A>G Q106R Missense
rs143995288 319G>A G107S Missense
rs768088765 323A>G K108R Missense
rs200900452 326C>T P109L Missense
rs759134978 328G>A E110K Missense
rs776274160 332T>C L111P Missense
rs370586022 340T>C F114L Missense
rs764544630 344_345insA N115Kfs Frameshift 
rs760255766 359A>G N120S Missense
rs772012403 361C>T Q121stop Stop gained
rs149510387 365A>G D122G Missense
rs774273098 366T>G D122E Missense
rs548757558 377C>T A126V Missense
1Information collected in January 2017; 2Inserted sequence TGAGCT 
TTTCTTTTTTACATGCCCTGCAATAGAGACTGGGTTGA.
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of the treatment revealed that oleuropein avoids HIF1α 
downregulation of miR-519, in turn decreasing PDRG1 
levels in the cells and favoring sensitivity to irradiation 
both in the cells and in tumor xenografts. 
PDRG1 in liver disease
Pdrg1 expression has also been analyzed in models 
of liver disease, where the Mat1a to Mat2a expression 
switch was detected together with oxidative stress. 
The results reported to date indicate no significant 
alteration of hepatic Pdrg1 levels in early stages of a 
model of Wilson disease, the Long Evans Cinnamon 
rats, despite the evident accumulation of copper[20]. 
However, acute liver injury induced by D-galactosamine 
intoxication induced the Mat expression switch, nuclear 
accumulation of MATα1 and the upregulation of Pdrg1 
expression and its nuclear levels[20]. Of note, the 
upregulation of Pdrg1 reported in this model was more 
modest than that measured in hepatoma cells.
PDRG1 in T cell selection
Autoimmune diseases present altered T cell selection 
mechanisms that have been explored using microarrays 
and animal models such as the non-obese diabetic 
(NOD) mice[69]. Thymocytes obtained from this model of 
human autoimmune diabetes have a reduced number 
of genes allowing distinction between positive and 
negative T cell selection compared to cells from a control 
mouse strain. This fact was especially important in the 
negative selection gene set, which included Pdgr1. Basal 
Pdrg1 expression was reduced in NOD thymocytes, and 
this gene was also identified among the high-quality 
candidates for D2mit490-linked defective thymic deletion, 
D2mit490 being a marker for the loci contributing to the 
defective negative selection detected in NOD mice[69]. 
CONCLUSION
PDRG1 is a member of the R2TP/prefoldin-like complex 
with nucleocytoplasmic distribution. In acute liver injury 
and a variety of tumors, high levels of PDRG1 expression 
have been detected. Several protein-protein interactions 
involving PDRG1 have been found while exploring the 
components of multiprotein complexes, putatively linking 
this protein to processes such as splicing, apoptosis 
and nutrient signaling. However, the role of these 
interactions and how and when do they occur remains 
unclear. Increased PDRG1 expression correlates with 
decreased levels of AdoMet, the main cellular methyl 
donor. Moreover, this increased expression also correlates 
with nuclear accumulation of MATα1 and with changes 
in epigenetic methylations that may be of a different 
sign depending on the AdoMet affinity of each specific 
methyltransferase. Such behavior can be explained by 
the decreased capacity for AdoMet synthesis exhibited by 
the MAT isoenzymes upon their interaction with PDRG1. 
This modulatory role of AdoMet levels is the first function 
ascribed to PDRG1. The fact that this interaction is 
restricted to the nucleus may exert a counteracting effect 
on liver pathology, precluding the objectives pursued 
by the nuclear accumulation of MATα1. Moreover, the 
interest and impact of this nuclear interaction could 
be of major importance for most cells, where PDRG1 
expression is higher and MATα1 localization is restricted 
to this compartment. Altogether, the aspects that 
deserve further attention include the identification of 
the interaction surfaces in complexes involving PDRG1, 
how the interactions are regulated, and the structure of 
the oncogene or its regulation. Knowledge of structural 
features may be of use for the design of new therapeutic 
options that, for example, interfere with pathological 
protein-protein interactions involving PDRG1.
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